Endo Announces Extension Of U.S. Rights For Voltaren® Gel
Grants Exclusive License to Commercialize Branded Product and any Future Authorized Generic Until 2023
Voltaren® Gel is the Most Prescribed FDA-Approved Topical NSAID for the Relief of Osteoarthritis Pain
"We are very proud of Voltaren® Gel's market leading position and are therefore very pleased to extend our marketing rights and continue this successful commercialization," said
Under the terms of the seven-year agreement,
Osteoarthritis (OA) is a chronic condition that occurs more frequently as people get older and can break down joints' protective cartilage causing damage and pain. OA pain develops slowly and can gradually worsen over time.
About Voltaren® Gel
Voltaren® Gel is a non-steroidal anti-inflammatory drug (NSAID) used for the relief of joint pain of osteoarthritis in the knees, ankles, feet, elbows, wrists, and hands. Voltaren® Gel has not been studied for use on the spine, hip, or shoulder. Voltaren® Gel received regulatory approval in
Important Safety Information About Voltaren® Gel
NSAID medicines, like Voltaren® Gel, may increase the chance of a heart attack or stroke that can lead to death. This chance increases:
- with longer use of NSAID medicines
- in people who have heart disease
NSAID medicines, like Voltaren® Gel, should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)."
NSAID medicines, like Voltaren® Gel, can cause ulcers and bleeding in the stomach and intestines at any time during treatment.
- Ulcers and bleeding can happen without warning symptoms and may cause death
- The chance of a person getting an ulcer or bleeding increases with older age
NSAID medicines should only be used:
- at the lowest dose possible for your treatment
- for the shortest time needed
Do not use Voltaren® Gel if you are allergic to diclofenac (the active ingredient in Voltaren® Gel) or if you have had asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs.
Tell your healthcare provider:
- if you have a history of ulcers or bleeding in the stomach or intestines, or kidney or liver problems, or heart failure
- about all of your medical conditions
- about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects
- if you are pregnant or breastfeeding. Voltaren® Gel should not be used late in pregnancy
NSAIDs, including Voltaren® Gel, can lead to high blood pressure or worsening of high blood pressure, which may add to the increased risk of heart attack and stroke.
Possible serious side effects include life-threatening skin and allergic reactions.
Get emergency help right away if you have any of the following symptoms: shortness of breath or trouble breathing, chest pain, weakness in one side of your body, slurred speech, or swelling of the face or throat. Stop using Voltaren® Gel and call your healthcare provider right away if you have: skin rash or fever with blisters.
Do not use Voltaren® Gel on the same skin site that was treated with other topical products, such as sunscreens, cosmetics, lotions, moisturizers, or insect repellents.
Other information about NSAIDs:
- Aspirin, which is an NSAID, can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines
You should not use Voltaren® Gel with oral NSAIDs.
The most common side effects reported in studies using Voltaren® Gel were application site reactions, including dermatitis (reported in 7% of treated patients).
Use Voltaren® Gel exactly as prescribed by your healthcare provider.
- Apply Voltaren® Gel to clean, dry skin that does not have any cuts, infections, or rashes
- Avoid exposing skin where you apply Voltaren® Gel to sunlight and artificial light, such as tanning booths
- Do not get Voltaren® Gel in your eyes, nose, and mouth
You are encouraged to report negative side effects of prescription drugs to the
For additional information about Voltaren® Gel, please see the full prescribing information at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60045fc6-f0d9-4f67-ba91-c3b317596437, including the Medication Guide.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation, including the statements by Mr. De Silva and other statements regarding market and product potential. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endo-announces-extension-of-us-rights-for-voltaren-gel-300192178.html
Investors/Media: Keri P. Mattox, (484) 216-7912; Media: Heather Zoumas-Lubeski, (484) 216-6829